Lumature Wealth Partners LLC Increases Position in Eli Lilly and Company (NYSE:LLY)

Lumature Wealth Partners LLC increased its stake in Eli Lilly and Company (NYSE:LLYGet Rating) by 4.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,033 shares of the company’s stock after purchasing an additional 164 shares during the quarter. Lumature Wealth Partners LLC’s holdings in Eli Lilly and were worth $1,114,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Wagner Wealth Management LLC raised its holdings in shares of Eli Lilly and by 59.4% in the 3rd quarter. Wagner Wealth Management LLC now owns 110 shares of the company’s stock worth $28,000 after purchasing an additional 41 shares during the period. AllSquare Wealth Management LLC bought a new stake in shares of Eli Lilly and in the 4th quarter worth approximately $28,000. Leverty Financial Group LLC bought a new stake in shares of Eli Lilly and in the 4th quarter worth approximately $29,000. FSB Premier Wealth Management Inc. bought a new stake in shares of Eli Lilly and in the 4th quarter worth approximately $30,000. Finally, Bell Investment Advisors Inc bought a new stake in shares of Eli Lilly and in the 3rd quarter worth approximately $32,000. 82.75% of the stock is currently owned by institutional investors.

Shares of NYSE:LLY opened at $291.63 on Friday. Eli Lilly and Company has a 52-week low of $193.11 and a 52-week high of $314.00. The firm has a fifty day moving average of $289.22 and a 200 day moving average of $266.38. The firm has a market capitalization of $277.10 billion, a PE ratio of 43.20, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27.

Eli Lilly and (NYSE:LLYGet Rating) last announced its earnings results on Thursday, April 28th. The company reported $2.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.30. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. The company had revenue of $7.81 billion during the quarter, compared to analyst estimates of $7.29 billion. During the same period in the previous year, the business earned $1.87 earnings per share. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. On average, sell-side analysts forecast that Eli Lilly and Company will post 8.25 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 10th. Investors of record on Monday, May 16th will be given a $0.98 dividend. The ex-dividend date of this dividend is Friday, May 13th. This represents a $3.92 annualized dividend and a yield of 1.34%. Eli Lilly and’s dividend payout ratio (DPR) is presently 58.07%.

In other Eli Lilly and news, SVP Ilya Yuffa sold 1,000 shares of the company’s stock in a transaction dated Tuesday, February 15th. The shares were sold at an average price of $237.45, for a total transaction of $237,450.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Donald A. Zakrowski sold 1,660 shares of the company’s stock in a transaction dated Friday, February 25th. The shares were sold at an average price of $243.84, for a total transaction of $404,774.40. The disclosure for this sale can be found here. Insiders sold 1,088,551 shares of company stock valued at $307,943,730 over the last quarter. 0.12% of the stock is owned by company insiders.

A number of research firms recently commented on LLY. The Goldman Sachs Group lifted their price target on shares of Eli Lilly and from $234.00 to $264.00 and gave the stock a “neutral” rating in a report on Tuesday, April 12th. Morgan Stanley boosted their target price on shares of Eli Lilly and from $364.00 to $369.00 in a report on Friday, April 29th. Daiwa Capital Markets started coverage on shares of Eli Lilly and in a report on Thursday, March 10th. They set an “outperform” rating and a $286.00 target price on the stock. Bank of America boosted their target price on shares of Eli Lilly and from $300.00 to $315.00 in a report on Thursday, March 17th. Finally, StockNews.com cut shares of Eli Lilly and from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 30th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Eli Lilly and presently has a consensus rating of “Buy” and an average target price of $302.56.

Eli Lilly and Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.